GSK heart drug disappoints in study, shingles vaccine on track

LONDON, Oct 27 (Reuters) - An experimental heart drug from GlaxoSmithKline called losmapimod failed to work as hoped in the first part of a large clinical trial, the company said on Tuesday, dealing a blow to its pipeline of new medicines.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.